{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T00:57:38Z","timestamp":1790470658171,"version":"4.1.0"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,6,22]],"date-time":"2020-06-22T00:00:00Z","timestamp":1592784000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Incyte Corporation"},{"name":"Incyte Corporation"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Immunology"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.clim.2020.108517","type":"journal-article","created":{"date-parts":[[2020,6,23]],"date-time":"2020-06-23T03:26:13Z","timestamp":1592882773000},"page":"108517","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":84,"special_numbering":"C","title":["Inhibition of cytokine signaling by ruxolitinib and implications for COVID-19 treatment"],"prefix":"10.1016","volume":"218","author":[{"given":"Swamy","family":"Yeleswaram","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Burn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryanne","family":"Covington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish","family":"Juvekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanlong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peg","family":"Squier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Langmuir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clim.2020.108517_bb0005","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1002\/jmv.25685","article-title":"Coronavirus infections and immune responses","volume":"92","author":"Li","year":"2020","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.clim.2020.108517_bb0010","author":"World Health Organization"},{"key":"10.1016\/j.clim.2020.108517_bb0015","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1056\/NEJMoa2002032","article-title":"Clinical characteristics of coronavirus disease 2019 in China","volume":"382","author":"Guan","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2020.108517_bb0020","doi-asserted-by":"crossref","first-page":"833","DOI":"10.3390\/v4050833","article-title":"Regulatory T cells in arterivirus and coronavirus infections: do they protect against disease or enhance it?","volume":"4","author":"Cecere","year":"2012","journal-title":"Viruses"},{"key":"10.1016\/j.clim.2020.108517_bb0025","first-page":"370","article-title":"Acute respiratory distress revealing antisynthetase syndrome","volume":"73","author":"Maloir","year":"2018","journal-title":"Rev. Med. Liege"},{"key":"10.1016\/j.clim.2020.108517_bb0030","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1093\/nsr\/nwaa041","article-title":"Pathogenic T cells and inflammatory monocytes incite inflammatory storm in severe COVID-19 patients","volume":"7","author":"Zhou","year":"2020","journal-title":"Natl. Sci. Rev."},{"key":"10.1016\/j.clim.2020.108517_bb0035","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.clim.2020.108517_bb0040","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/S2213-2600(20)30076-X","article-title":"Pathological findings of COVID-19 associated with acute respiratory distress syndrome","volume":"8","author":"Xu","year":"2020","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.clim.2020.108517_bb0045","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa2001017","article-title":"A novel coronavirus from patients with pneumonia in China, 2019","volume":"382","author":"Zhu","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2020.108517_bb0050","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1007\/s00134-020-05991-x","article-title":"Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China","volume":"46","author":"Ruan","year":"2020","journal-title":"Intensive Care Med."},{"key":"10.1016\/j.clim.2020.108517_bb0055","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/j.1600-065X.2008.00644.x","article-title":"Therapeutic targeting of Janus kinases","volume":"223","author":"Pesu","year":"2008","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.clim.2020.108517_bb0060","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.semcdb.2008.07.002","article-title":"JAKs in pathology: role of Janus kinases in hematopoietic malignancies and immunodeficiencies","volume":"19","author":"Vainchenker","year":"2008","journal-title":"Semin. Cell Dev. Biol."},{"key":"10.1016\/j.clim.2020.108517_bb0065","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1093\/intimm\/dxh102","article-title":"SOCS-1 suppresses TNF-\u03b1-induced apoptosis through the regulation of Jak activation","volume":"16","author":"Kimura","year":"2004","journal-title":"Int. Immunol."},{"key":"10.1016\/j.clim.2020.108517_bb0070","first-page":"13","article-title":"Tumor necrosis factor \u03b1 (TNF-\u03b1) activates Jak1\/Stat3-Stat5B signaling through TNFR-1 in human B cells","volume":"13","author":"Miscia","year":"2002","journal-title":"Cell Growth Differ."},{"key":"10.1016\/j.clim.2020.108517_bb0075","unstructured":"Jakafi (ruxolitinib) [package insert]. Incyte Corporation, Wilmington, DE, 2019."},{"key":"10.1016\/j.clim.2020.108517_bb0080","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1182\/blood-2009-04-214957","article-title":"Preclinical characterization of the selective JAK1\/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms","volume":"115","author":"Quint\u00e1s-Cardama","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clim.2020.108517_bb0085","doi-asserted-by":"crossref","first-page":"3832","DOI":"10.1182\/blood-2013-12-543736","article-title":"Activity of therapeutic JAK 1\/2 blockade in graft-versus-host disease","volume":"123","author":"Spoerl","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clim.2020.108517_bb0090","doi-asserted-by":"crossref","unstructured":"Juvekar A, Ruggeri B, Condon S, Borkowski A, Huber R, Smith P. Ruxolitinib, a JAK1\/JAK2 selective inhibitor is highly efficacious in corticosteroid untreated and refractory MHC-mismatched mouse model of acute GVHD [abstract 4523]. In: American Society of Hematology 60th Annual Meeting, (December 1\u20134, 2018; San Diego, CA, USA).","DOI":"10.1182\/blood-2018-99-112223"},{"key":"10.1016\/j.clim.2020.108517_bb0095","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0109799","article-title":"Pharmacologic blockade of JAK1\/JAK2 reduces GVHD and preserves the graft-versus-leukemia effect","volume":"9","author":"Choi","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.clim.2020.108517_bb0100","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa1002028","article-title":"Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis","volume":"363","author":"Verstovsek","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2020.108517_bb0105","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","article-title":"JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis","volume":"366","author":"Harrison","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2020.108517_bb0110","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1080\/13543784.2020.1757069","article-title":"Ruxolitinib: a potential treatment for corticosteroid refractory acute graft-versus-host disease","volume":"29","author":"Abedin","year":"2020","journal-title":"Exp. Opin. Investig. Drugs"},{"key":"10.1016\/j.clim.2020.108517_bb0115","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1182\/blood.2020004823","article-title":"Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label, phase 2 trial","volume":"135","author":"Jagasia","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clim.2020.108517_bb0120","series-title":"61st ASH Annual Meeting & Exposition","article-title":"Stratification of responders and non-responders in the REACH-1 trial based on serum proteomic analysis [abstract 4531]","author":"Owens","year":"2020"},{"key":"10.1016\/j.clim.2020.108517_bb0125","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1111\/ped.13064","article-title":"Hemophagocytic lymphohistiocytosis: pathogenesis, diagnosis, and management","volume":"58","author":"Morimoto","year":"2016","journal-title":"Pediatr. Int."},{"key":"10.1016\/j.clim.2020.108517_bb0130","doi-asserted-by":"crossref","first-page":"e210","DOI":"10.3324\/haematol.2019.222471","article-title":"Ruxolitinib for refractory\/relapsed hemophagocytic lymphohistiocytosis","volume":"105","author":"Wang","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.clim.2020.108517_bb0135","doi-asserted-by":"crossref","first-page":"e630","DOI":"10.1016\/S2352-3026(19)30156-5","article-title":"Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trial","volume":"6","author":"Ahmed","year":"2019","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clim.2020.108517_bb0140","doi-asserted-by":"crossref","first-page":"4131","DOI":"10.1182\/bloodadvances.2019000898","article-title":"Resolution of secondary hemophagocytic lymphohistiocytosis after treatment with the JAK1\/2 inhibitor ruxolitinib","volume":"3","author":"Goldsmith","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.clim.2020.108517_bb0145","author":"ClinicalTrials.gov, (NCT04320615)"},{"key":"10.1016\/j.clim.2020.108517_bb0150","author":"ClinicalTrials.gov, (NCT04327388)"},{"key":"10.1016\/j.clim.2020.108517_bb0155","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s40259-019-00333-w","article-title":"Selective JAKinibs: prospects in inflammatory and autoimmune diseases","volume":"33","author":"Virtanen","year":"2019","journal-title":"Biodrugs"},{"key":"10.1016\/j.clim.2020.108517_bb0160","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0222944","article-title":"Comparative phenotypic profiling of the JAK2 inhibitors ruxolitinib, fedratinib, momelotinib, and pacritinib reveals distinct mechanistic signatures","volume":"14","author":"Singer","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.clim.2020.108517_bb0165","series-title":"Bristol Myers Squibb","author":"Inrebic (fedratinib) [prescribing information]","year":"2019"},{"key":"10.1016\/j.clim.2020.108517_bb0170","unstructured":"Xeljanz (tofacitinib) [package insert]. Pfizer, New York, NY, 2019."},{"key":"10.1016\/j.clim.2020.108517_bb0175","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1056\/NEJMoa1409002","article-title":"Ruxolitinib versus standard therapy for the treatment of polycythemia vera","volume":"372","author":"Vannucchi","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2020.108517_bb0180","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1056\/NEJMoa1917635","article-title":"Ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease","volume":"382","author":"Zeiser","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2020.108517_bb0185","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1177\/0091270010389469","article-title":"The pharmacokinetics, pharmacodynamics, and safety of orally dosed INCB018424 phosphate in healthy volunteers","volume":"51","author":"Shi","year":"2011","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.clim.2020.108517_bb0190","unstructured":"Actemra (tocilizumab) [package insert]. Genentech, Inc., South San Francisco, CA, 2013."},{"key":"10.1016\/j.clim.2020.108517_bb0195","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1002\/jcph.218","article-title":"A randomized, placebo-controlled study of the pharmacokinetics, pharmacodynamics, and tolerability of the oral JAK2 inhibitor fedratinib (SAR302503) in healthy volunteers","volume":"54","author":"Zhang","year":"2014","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.clim.2020.108517_bb0200","doi-asserted-by":"crossref","first-page":"3740","DOI":"10.1158\/1078-0432.CCR-14-2758","article-title":"Pharmacologic inhibition of JAK1\/JAK2 signaling reduces experimental murine acute GVHD while preserving GVT effects","volume":"21","author":"Carniti","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.clim.2020.108517_bb0205","author":"Adnkronos"},{"key":"10.1016\/j.clim.2020.108517_bb0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2020.05.019","article-title":"Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): a multicenter, single-blind, randomized controlled trial","author":"Cao","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.clim.2020.108517_bb0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.106023","article-title":"Side effects of ruxolitinib in patients with SARS-CoV-2 infection: two case reports","author":"Gaspari","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.clim.2020.108517_bb0220","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1038\/s41375-020-0891-0","article-title":"The Janus kinase 1\/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation","volume":"34","author":"La Ros\u00e9e","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.clim.2020.108517_bb0225","author":"Won"}],"container-title":["Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661620303971?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661620303971?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T16:01:08Z","timestamp":1761494468000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521661620303971"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":45,"alternative-id":["S1521661620303971"],"URL":"https:\/\/doi.org\/10.1016\/j.clim.2020.108517","relation":{},"ISSN":["1521-6616"],"issn-type":[{"value":"1521-6616","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inhibition of cytokine signaling by ruxolitinib and implications for COVID-19 treatment","name":"articletitle","label":"Article Title"},{"value":"Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clim.2020.108517","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"108517"}}